Symphogen as - Strategic SWOT Analysis Review


Naperville, IL -- (SBWIRE) -- 01/17/2014 -- Reportstack, provider of premium market research reports announces the addition of Symphogen AS - Strategic SWOT Analysis Review market report to its offering
Symphogen AS - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the companys key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.


- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy summarization of the companys business strategy.
- SWOT analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities A list of key manufacturing facilities of the company.


Symphogen A/S (Symphogen) is a biopharmaceutical company. The company develops antibody therapeutics such as monoclonal, monoclonal mixtures and polyclonal for the treatment of cancer, infectious and autoimmune diseases. It develops antibody therapeutics based on its three proprietary platforms such as Symplex discovery, SymSelect functional and Sympress technology. Symphogens product pipeline includes Rozrolimupab (Sym001), Rozrolimopab / HDN, Sym002, Sym004, Sym005, Sym006, Sym008, Sym009 and Sym014.

Symphogen AS Key Recent Developments

Dec 20, 2013: Symphogen Announces the Appointment of Annika Espander Jansson as Non-Executive Director
Apr 10, 2013: Symphogen Presents New Pan-HER Data At Annual AACR Meeting 2013
Sep 03, 2012: Symphogen Enters Project Supported By Danish National Advanced Technology Foundation
Apr 02, 2012: Symphogen Appoints Martin Olin As CFO
Mar 06, 2012: Symphogen Reports Revenue Of DKK9.1m In 2011

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this reports analysis of the companys business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors business structure and strategies with detailed SWOT analysis. In this, the companys core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this reports detailed insight into the companys strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604